Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis

Knee Osteoarthrosis Clinical Trial

Official title: Knee Osteoarthrosis (KOA) in Jordanian Patients: a Phase I Dose-finding Study Using Wharton Jelly Derived Mesenchymal Stem Cells (WJMSC) for Advanced Stage III and IV KOA

Status Recruiting

Clinical Trial Summary

Wharton Jelly derived Mesenchymal Stem Cells (WJMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Clinical Trial Description

Ten patients from both genders diagnosed with Knee osteoarthrosis, will be enrolled according to strict inclusion and exclusion criteria. These patients will be injected with Wharton Jelly derived Mesenchymal Stem Cells. Then, they are followed by clinical assessment, laboratory investigations as well as magnetic resonance imaging (MRI) of the injected knee. ;

Related Conditions & MeSH terms

• Knee Osteoarthrosis
• Osteoarthritis
• Osteoarthritis, Knee

• NCT number: NCT02963727
• Study type: Interventional
• Source: University of Jordan
• Contact: Hanan Jafar, PhD
• Phone: 00962798871087
• Email: hanan.jafar@gmail.com
• Status: Recruiting
• Phase: Phase 1
• Start date: January 27, 2017
• Completion date: December 2021